{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T05:41:19Z","timestamp":1791438079906,"version":"4.3.3"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T00:00:00Z","timestamp":1728345600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"name":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Am J Clin Dermatol"],"published-print":{"date-parts":[[2024,11]]},"DOI":"10.1007\/s40257-024-00885-w","type":"journal-article","created":{"date-parts":[[2024,10,8]],"date-time":"2024-10-08T15:01:57Z","timestamp":1728399717000},"page":"987-996","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Pembrolizumab for the First-Line Treatment of Recurrent Locally Advanced or Metastatic Merkel Cell Carcinoma: Results from the Single-Arm, Open-Label, Phase III KEYNOTE-913 Study"],"prefix":"10.1007","volume":"25","clinical-trial-number":[{"clinical-trial-number":"nct03783078","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Laurent","family":"Mortier","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lisa","family":"Villabona","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ben","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Arance","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcus O.","family":"Butler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marie","family":"Beylot-Barry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Saiag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mahtab","family":"Samimi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paolo A.","family":"Ascierto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Spada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"De Pontville","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Maio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alfonso","family":"Berrocal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Espinosa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jaume","family":"Capdevila","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Max","family":"Levin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Debasmita","family":"Das","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clemens","family":"Krepler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dmitri","family":"Grebennik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanna","family":"Chiarion-Sileni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,8]]},"reference":[{"issue":"4","key":"885_CR1","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1001\/jamadermatol.2021.6096","volume":"158","author":"AM Mcevoy","year":"2022","unstructured":"Mcevoy AM, Lachance K, Hippe DS, Cahill K, Moshiri Y, Lewis CW, et al. Recurrence and mortality risk of Merkel cell carcinoma by cancer stage and time from diagnosis. JAMA Dermatol. 2022;158(4):382\u20139.","journal-title":"JAMA Dermatol"},{"issue":"4","key":"885_CR2","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1002\/cam4.2781","volume":"9","author":"CW Lewis","year":"2020","unstructured":"Lewis CW, Qazi J, Hippe DS, Lachance K, Thomas H, Cook MM, et al. Patterns of distant metastases in 215 Merkel cell carcinoma patients: implications for prognosis and surveillance. Cancer Med. 2020;9(4):1374\u201382.","journal-title":"Cancer Med"},{"issue":"11","key":"885_CR3","doi-asserted-by":"publisher","first-page":"3564","DOI":"10.1245\/s10434-016-5266-4","volume":"23","author":"KL Harms","year":"2016","unstructured":"Harms KL, Healy MA, Nghiem P, Sober AJ, Johnson TM, Bichakjian CK, et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann Surg Oncol. 2016;23(11):3564\u201371.","journal-title":"Ann Surg Oncol"},{"key":"885_CR4","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1146\/annurev-pathmechdis-012419-032817","volume":"16","author":"D Ja","year":"2021","unstructured":"DeCaprio JA. Molecular pathogenesis of Merkel cell carcinoma. Annu Rev Pathol. 2021;16:69\u201391.","journal-title":"Annu Rev Pathol"},{"issue":"11","key":"885_CR5","doi-asserted-by":"publisher","first-page":"1363","DOI":"10.2217\/fon-2020-1036","volume":"17","author":"SY Park","year":"2021","unstructured":"Park SY, Doolittle-Amieva C, Moshiri Y, Akaike T, Parvathaneni U, Bhatia S, et al. How we treat Merkel cell carcinoma: within and beyond current guidelines. Future Oncol. 2021;17(11):1363\u201377.","journal-title":"Future Oncol"},{"issue":"4","key":"885_CR6","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1080\/14737140.2018.1445528","volume":"18","author":"M Baker","year":"2018","unstructured":"Baker M, Cordes L, Brownell I. Avelumab: a new standard for treating metastatic merkel cell carcinoma. Expert Rev Anticancer Ther. 2018;18(4):319\u201326.","journal-title":"Expert Rev Anticancer Ther"},{"issue":"10","key":"885_CR7","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","volume":"17","author":"HL Kaufman","year":"2016","unstructured":"Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, Dangelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17(10):1374\u201385.","journal-title":"Lancet Oncol"},{"issue":"7","key":"885_CR8","doi-asserted-by":"publisher","first-page":"e002646","DOI":"10.1136\/jitc-2021-002646","volume":"9","author":"SP D'angelo","year":"2021","unstructured":"D\u2019Angelo SP, Lebb\u00e9 C, Mortier L, Brohl AS, Fazio N, Grob JJ, et al. First-line avelumab in a cohort of 116 patients with metastatic Merkel cell carcinoma (JAVELIN Merkel 200): primary and biomarker analyses of a phase II study. J Immunother Cancer. 2021;9(7):e002646.","journal-title":"J Immunother Cancer"},{"issue":"26","key":"885_CR9","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.1056\/NEJMoa1603702","volume":"374","author":"PT Nghiem","year":"2016","unstructured":"Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374(26):2542\u201352.","journal-title":"N Engl J Med"},{"issue":"7","key":"885_CR10","doi-asserted-by":"publisher","first-page":"e1077","DOI":"10.1634\/theoncologist.2020-0184","volume":"25","author":"D Bradford","year":"2020","unstructured":"Bradford D, Demko S, Jin S, Mishra-Kalyani P, Beckles AR, Goldberg KB, et al. FDA accelerated approval of pembrolizumab for recurrent locally advanced or metastatic Merkel cell carcinoma. Oncologist. 2020;25(7):e1077\u201382.","journal-title":"Oncologist"},{"issue":"4","key":"885_CR11","doi-asserted-by":"publisher","first-page":"e002478","DOI":"10.1136\/jitc-2021-002478","volume":"9","author":"P Nghiem","year":"2021","unstructured":"Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Three-year survival, correlates and salvage therapies in patients receiving first-line pembrolizumab for advanced Merkel cell carcinoma. J Immunother Cancer. 2021;9(4):e002478.","journal-title":"J Immunother Cancer"},{"issue":"13_Supplement","key":"885_CR12","doi-asserted-by":"publisher","first-page":"CT074","DOI":"10.1158\/1538-7445.AM2017-CT074","volume":"77","author":"SL Topalian","year":"2017","unstructured":"Topalian SL, Bhatia S, Hollebecque A, Awada A, Boer JPD, Kudchadkar RR, et al. Abstract CT074: non-comparative, open-label, multiple cohort, phase 1\/2 study to evaluate nivolumab (nivo) in patients with virus-associated tumors (CheckMate 358): efficacy and safety in Merkel cell carcinoma (MCC). Cancer Res. 2017;77(13_Supplement):CT074.","journal-title":"Cancer Res"},{"issue":"22","key":"885_CR13","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1200\/JCO.20.00201","volume":"38","author":"SL Topalian","year":"2020","unstructured":"Topalian SL, Bhatia S, Amin A, Kudchadkar RR, Sharfman WH, Lebb\u00e9 C, et al. Neoadjuvant nivolumab for patients with resectable Merkel cell carcinoma in the checkmate 358 trial. J Clin Oncol. 2020;38(22):2476\u201387.","journal-title":"J Clin Oncol"},{"key":"885_CR14","doi-asserted-by":"publisher","first-page":"S686","DOI":"10.1016\/j.annonc.2023.09.2280","volume":"34","author":"G Grignani","year":"2023","unstructured":"Grignani G, Rutkowski P, Lebbe C, Guida M, Gaudy Marqueste C, De Braud FGM, et al. Updated results from POD1UM-201: a phase II study of retifanlimab in patients with advanced or metastatic Merkel cell carcinoma (MCC). Ann Oncol. 2023;34:S686.","journal-title":"Ann Oncol"},{"issue":"2","key":"885_CR15","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1007\/s11864-013-0225-9","volume":"14","author":"NJ Miller","year":"2013","unstructured":"Miller NJ, Bhatia S, Parvathaneni U, Iyer JG, Nghiem P. Emerging and mechanism-based therapies for recurrent or metastatic Merkel cell carcinoma. Curr Treat Options Oncol. 2013;14(2):249\u201363.","journal-title":"Curr Treat Options Oncol"},{"issue":"5","key":"885_CR16","doi-asserted-by":"publisher","first-page":"733","DOI":"10.1007\/s40258-019-00492-5","volume":"17","author":"L Steuten","year":"2019","unstructured":"Steuten L, Garmo V, Phatak H, Sullivan SD, Nghiem P, Ramsey SD. Treatment patterns, overall survival, and total healthcare costs of advanced Merkel cell carcinoma in the USA. Appl Health Econ Health Policy. 2019;17(5):733\u201340.","journal-title":"Appl Health Econ Health Policy"},{"issue":"9","key":"885_CR17","doi-asserted-by":"publisher","first-page":"2294","DOI":"10.1002\/cam4.815","volume":"5","author":"JG Iyer","year":"2016","unstructured":"Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, Anderson A, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5(9):2294\u2013301.","journal-title":"Cancer Med"},{"issue":"19","key":"885_CR18","doi-asserted-by":"publisher","first-page":"1699","DOI":"10.2217\/fon-2017-0187","volume":"13","author":"CL Cowey","year":"2017","unstructured":"Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol. 2017;13(19):1699\u2013710.","journal-title":"Future Oncol"},{"issue":"9","key":"885_CR19","doi-asserted-by":"publisher","first-page":"693","DOI":"10.1200\/JCO.18.01896","volume":"37","author":"P Nghiem","year":"2019","unstructured":"Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Brohl AS, et al. Durable tumor regression and overall survival in patients with advanced Merkel cell carcinoma receiving pembrolizumab as first-line therapy. J Clin Oncol. 2019;37(9):693\u2013702.","journal-title":"J Clin Oncol"},{"key":"885_CR20","unstructured":"U.S. Food & Drug Administration. FDA grants accelerated approval toretifanlimab-dlwr for metastatic or recurrent locally advanced Merkel cellcarcinoma. Silver Spring, MD: U.S. Food & Drug Administration; 2023. https:\/\/www.fda.gov\/drugs\/resources-information-approved-drugs\/fda-grants-accelerated-approval-retifanlimab-dlwr-metastatic-or-recurrent-locally-advanced-merkel."},{"key":"885_CR21","first-page":"149","volume":"14","author":"R Lohray","year":"2023","unstructured":"Lohray R, Verma KK, Wang LL, Haynes D, Lewis DJ. Avelumab for advanced Merkel cell carcinoma: global real-world data on patient response and survival. Pragmat Obs Res. 2023;14:149\u201354.","journal-title":"Pragmat Obs Res."},{"issue":"8","key":"885_CR22","doi-asserted-by":"publisher","first-page":"e004904","DOI":"10.1136\/jitc-2022-004904","volume":"10","author":"S Bhatia","year":"2022","unstructured":"Bhatia S, Nghiem P, Veeranki SP, Vanegas A, Lachance K, Tachiki L, et al. Real-world clinical outcomes with avelumab in patients with Merkel cell carcinoma treated in the USA: a multicenter chart review study. J Immunother Cancer. 2022;10(8):e004904.","journal-title":"J Immunother Cancer"},{"issue":"9","key":"885_CR23","doi-asserted-by":"publisher","first-page":"e1633","DOI":"10.1002\/onco.13845","volume":"26","author":"A Bhanegaonkar","year":"2021","unstructured":"Bhanegaonkar A, Liu FX, Boyd M, Fulcher N, Kim R, Krulewicz S, et al. Real-world clinical outcomes in patients with locally advanced or metastatic Merkel cell carcinoma treated in U.S. oncology clinical practices: results from SPEAR-Merkel. Oncologist. 2021;26(9):e1633\u201343.","journal-title":"Oncologist"},{"key":"885_CR24","doi-asserted-by":"publisher","first-page":"182","DOI":"10.1016\/j.ejca.2020.11.010","volume":"144","author":"C Robert","year":"2021","unstructured":"Robert C, Hwu WJ, Hamid O, Ribas A, Weber JS, Daud AI, et al. Long-term safety of pembrolizumab monotherapy and relationship with clinical outcome: a landmark analysis in patients with advanced melanoma. Eur J Cancer. 2021;144:182\u201391.","journal-title":"Eur J Cancer"}],"container-title":["American Journal of Clinical Dermatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00885-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40257-024-00885-w\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40257-024-00885-w.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,25]],"date-time":"2024-10-25T10:25:36Z","timestamp":1729851936000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40257-024-00885-w"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,8]]},"references-count":24,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2024,11]]}},"alternative-id":["885"],"URL":"https:\/\/doi.org\/10.1007\/s40257-024-00885-w","relation":{},"ISSN":["1175-0561","1179-1888"],"issn-type":[{"value":"1175-0561","type":"print"},{"value":"1179-1888","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,8]]},"assertion":[{"value":"19 August 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 October 2024","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was funded by Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA. The funder participated in study design, data analysis and interpretation, and manuscript writing, and maintained the study database. All authors had full access to the data and had final responsibility for the decision to submit the manuscript for publication.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Laurent Mortier has received consulting fees and travel support from MSD, BMS, Novartis, and Pierre Fabre. Lisa Villabona, Marie Beylot-Barry, Francesca Spada, Michel De Pontville, and Enrique Espinosa declare that they have no conflicts of interest that might be relevant to the contents of this article. Ben Lawrence has received honoraria and travel support from MSD. Ana Arance has received research funding from MSD, honoraria from MSD and Merck Serono, and travel support from MSD and BMS. Marcus O. Butler has received research funding from Merck, Takara Bio, and Novartis; consulting fees from Bristol Myers Squibb, Merck, Novartis, Adaptimmune, Immunocore, GlaxoSmithKline, Sanofi, Sun Pharma, Instil Bio, IOVANCE, Pfizer, Ideaya Bio, Medison, LaRoche Possey, and Regeneron; and honoraria from Sanofi, Bristol Myers Squibb, Merck, Pfizer, and Novartis; and has participated on a safety review committee for Adaptimmune and GlaxoSmithKline. Philippe Saiag has received research funding and consulting fees from Merck Serono. Mahtab Samimi has received research funding from SOTIO and travel support from BMS and MSD, has participated on advisory boards for Merck and Pfizer, and is chair of EADV. Paolo A. Ascierto has received research support from Bristol Myers Squibb, Roche-Genentech, Pfizer, and Sanofi; consulting fees from Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, Merck Serono, Pierre-Fabre, Sun Pharma, Sanofi, Sandoz, Italfarmaco, Nektar, Pfizer, Lunaphore, Medicenna, Bio-Al Health, ValoTx, RepImmune, and Bayer; and travel support from Pfizer, Bio-AI Health, and RepImmune; and has participated on advisory boards for Bristol Myers Squibb, Roche-Genentech, Merck Sharp & Dohme, Novartis, AstraZeneca, Boehringer Ingelheim, Eisai, Regeneron, Daiichi Sankyo, Oncosec, Nouscom, Seagen, iTeos, and Erasca. Michele Maio has received consulting fees, honoraria, and travel support from, and has participated in advisory boards for, BMS, Roche, MSD, Merck, Sanofi, GSK, AstraZeneca, Pierre Fabre, Alfasigma, Eli Lilly, Amgen, Sciclone, Incyte, and Ionctura; and owns stock in Epigen and Teravance. Alfonso Berrocal has received consulting fees from MSD and BMS and honoraria and travel support from MSD. Jaume Capdevila has received research funding from Novartis, Pfizer, AstraZeneca, Advanced Accelerator Applications, Eisai, Amgen, and Bayer; and consulting fees from Novartis, Pfizer, Ipsen, Exelixis, Bayer, Eisai, Advanced Accelerator Applications, Amgen, Sanofi, Lilly, Huchinson Pharma, ITM, Advanz, Merck Serono, Esteve, and Roche. Max Levin has received lecturing fees from Bristol Myers Squibb, Roche, and Merck Sharp & Dohme. Debasmita Das is an employee of Merck & Co., Inc., Rahway, NJ, USA. Clemens Krepler is an employee of, and owns stock in, Merck & Co., Inc., Rahway, NJ, USA. Dmitri Grebennik is an employee of Merck & Co., Inc., Rahway, NJ, USA. Vanna Chiarion-Sileni has received travel support from Pierre-Fabre and Sanofi; has participated on advisory boards for Pierre-Fabre and Merck Sharp & Dohme.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study protocol and all amendments were approved by the appropriate institutional review board or ethics committee at each center (Table S2, see the electronic supplementary material). The study was conducted in accordance with the protocol, Good Clinical Practice Guidelines, and the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"All patients provided written informed consent.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"Not applicable.","order":6,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA (MSD) is committed to providing qualified scientific researchers access to anonymized data and clinical study reports from the company\u2019s clinical trials for the purpose of conducting legitimate scientific research. MSD is also obligated to protect the rights and privacy of trial participants and, as such, has a procedure in place for evaluating and fulfilling requests for sharing company clinical trial data with qualified external scientific researchers. The MSD data sharing website (available at: ) outlines the process and requirements for submitting a data request. Applications will be promptly assessed for completeness and policy compliance. Feasible requests will be reviewed by a committee of MSD subject matter experts to assess the scientific validity of the request and the qualifications of the requestors. In line with data privacy legislation, submitters of approved requests must enter into a standard data-sharing agreement with MSD before data access is granted. Data will be made available for request after product approval in the USA and EU or after product development is discontinued. There are circumstances that may prevent MSD from sharing requested data, including country or region-specific regulations. If the request is declined, it will be communicated to the investigator. Access to genetic or exploratory biomarker data requires a detailed, hypothesis-driven statistical analysis plan that is collaboratively developed by the requestor and MSD subject matter experts; after approval of the statistical analysis plan and execution of a data-sharing agreement, MSD will either perform the proposed analyses and share the results with the requestor or will construct biomarker covariates and add them to a file with clinical data that is uploaded to an analysis portal so that the requestor can perform the proposed analyses.","order":7,"name":"Ethics","group":{"name":"EthicsHeading","label":"Availability of data and material"}},{"value":"Not applicable.","order":8,"name":"Ethics","group":{"name":"EthicsHeading","label":"Code availability"}},{"value":"Acquisition of the data: LM, LV, BL, MOB, MB-B, PS, MS, FS, MD, MM, AB, EE, ML, DD, VCS. Analysis of the data: LM, PS, DD, CK, DG. Interpretation of the results: LM, LV, BL, AA, MB-B, PS, PAA, MM, JC, ML, DD, CK, DG, VCS. Drafting of the manuscript: LM, PS, DD. Critically reviewing or revising the manuscript for important intellectual content: LM, LV, BL, AA, MOB, MB-B, PS, MS, PAA, FS, MD, MM, AB, EE, JC, ML, DD, CK, DG, VCS.","order":9,"name":"Ethics","group":{"name":"EthicsHeading","label":"Author contributions"}}]}}